Lv4
420 积分 2024-10-23 加入
Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposure
13天前
已完结
Dual BRD4/AKT inhibition overcomes c-MYC-driven resistance in metastatic castration-resistant prostate cancer
1个月前
已关闭
Rational Design of Novel pyrazolo[4,3c]quinoline Derivatives as Potent, Selective, and Orally Bioavailable ATM Inhibitors with Promising In Vivo Efficacy
2个月前
已完结
Novel selective agents for the degradation of AR/AR-V7 to treat advanced prostate cancer
3个月前
已完结
Discovery of AZD8421: A Potent CDK2 Inhibitor with Selectivity Against Other CDK Family Members and the Human Kinome
6个月前
已完结
Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA
7个月前
已完结
CDK4/6 Inhibitors: Mechanisms of Resistance and Potential Biomarkers of Responsiveness in Breast Cancer
7个月前
已完结
A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib’s Journey from Discovery to Approval and What’s Next in CDK Inhibition in Breast Cancer
7个月前
已完结
PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer
8个月前
已完结
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
8个月前
已完结
皖公网安备34019202002308
